Vaginal DHEA for Gynecologic Cancer

This trial explores the effectiveness and safety of vaginal DHEA (Prasterone) in improving vaginal health for women who have undergone radiation treatment for gynecologic, anal, or rectal cancer. Radiation can cause issues like dryness, burning, and pain, similar to menopause symptoms. DHEA, a hormone therapy, may alleviate these problems. Women who are menopausal, have received specific cancer treatments, and experience these symptoms might be suitable candidates for this study. Participants will use a DHEA treatment for three months and provide vaginal swab samples during the trial. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to important findings.

You may need to stop certain medications before joining the trial. Specifically, you cannot use estrogen or progestin therapies, DHEA, or certain vaginal treatments for a period before starting the study. Check with the trial team for details on your specific medications.

Research has shown that using vaginal DHEA (a hormone) is generally safe for improving vaginal health. In one study, women who used vaginal DHEA for 12 weeks reported no major safety issues. The treatment was well-tolerated, with only mild side effects. Another study found that using DHEA vaginally alleviated symptoms like dryness and discomfort over 6 months without significant problems. These studies suggest that vaginal DHEA could be a safe option for managing vaginal symptoms after radiation treatment.¹²³⁴⁵

Unlike standard treatments for gynecologic cancer, which often involve surgery, radiation, or chemotherapy, Prasterone (DHEA) offers a unique approach by being administered vaginally. This method targets the affected area directly, potentially minimizing systemic side effects. Prasterone is a precursor hormone that can be converted into estrogen and other hormones locally, which may help improve symptoms and quality of life without the broader hormonal impacts. Researchers are excited about this treatment because it provides a potentially safer, more localized option for patients, focusing on targeted supportive care.

Research has shown that vaginal DHEA (prasterone) can improve vaginal health in women after menopause or cancer treatment. One study found that using vaginal DHEA for 12 weeks significantly enhanced sexual health and reduced symptoms like dryness, burning, and pain during sex. Another study demonstrated that cancer survivors using DHEA experienced better vaginal health and comfort without a significant rise in estrogen levels, which is important for safety. In this trial, participants will receive DHEA vaginally for 3 months. These findings suggest that DHEA could help treat vaginal issues caused by radiation treatment for gynecologic cancer.⁶⁷⁸⁹¹⁰